The Project to End Post Partum Breast Cancer
Many people are unfamiliar with Postpartum Breast Cancer (PPBC), a little-known subset of breast cancer that occurs in women within 10 years of childbirth. This episode of our podcast delves into this personal topic for several members of our team.
Drs. Virginia Borges and Pepper Schedin are launching the first-ever clinical trial to prevent PPBC. Their groundbreaking approach involves giving healthy new mothers a brief course of ibuprofen as they wean their babies from breastfeeding. This trial holds huge potential for global impact, and the doctors need the public’s help to make it happen.
MBC 101: Tumor Microenvironment with Dr. Amy Beumer
Have you ever wondered how our cancer metastasizes? Why is it that some treatments just don’t work? Can we as patients living with MBC alter cellular level activity? In this episode, you will hear the answers to these questions and more. Join us as we take a step back to the basics of tumor microenvironment with our guest, Dr. Amy Beumer, who will break down the science into smaller, digestible bites. In this lively discussion, Dr. Amy explains the how and the why of this tough topic. You will hear her say “This is fun” and use engaging, relatable metaphors like “Picture your neighborhood and that one neighbor…..” By the end, I assure you that you’ll walk away with a deeper understanding of tumor microenvironment than when you started.
Pull up a chair, listen in your car, or on your daily walk, we are with you wherever you listen to your podcasts. Terms and other resources are provided in the episode notes.
Biosimilars and Their Use in Cancer Treatment
On today's episode, we are thrilled to discuss an important and often misunderstood area of oncology- biosimilars and their increasing use in cancer care. You might be curious, what exactly are biosimilars? How are they developed and approved? And most importantly, how are they transforming the lives of patients diagnosed with cancer? We will break down these questions and more as we explore this with an overview from Dr. Julie Gralow, a breast medical oncologist and chief medical officer at the American Society of Clinical Oncology.
Tumor-Agnostic Therapies: Is The TAPUR Study Right For You?
For our Season 9 opening episode, we're learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the TAPUR Study. You may wonder, what is TAPUR and how does it relate to agnostic treatments? The pioneer behind the study, Dr. Schilsky, explains clinical trials for agnostic therapeutics, how you can join a TAPUR trial, and what to expect.
Tumor-Agnostic Therapies: Is This a Paradigm Shift in Cancer Care?
Do tumor-agnostic therapies represent a radical shift in oncology? Join us on this 1st part of a 2-part series as Dr. Joshua Drago of MSKCC answers this question and points out the advantages as well as the treatment limitations of agnostic therapeutics.
Report Back From ASCO 2024: What’s the Latest in HR+ MBC?
We are thrilled to present an audio version of SHARE Cancer Support’s webinar “Report Back from ASCO 2024: Latest Updates on HR+ Metastatic Breast Cancer (MBC)”.
This episode is an in-depth report from the ASCO 2024 Annual Meeting, featuring the latest advancements and research in HR+ MBC. Hear from Dr. Kevin Kalinsky as we dive into the findings from the DESTINY-Breast06 and postMONARCH trials, exploring their implications and potential impact on treatment strategies.
Tissue Donation - You can help advance MBC research
Today we talk with breast cancer researcher Dr. Steffi Oesterreich, clinical coordinator Lori Miller, and MBC advocates Stephanie Walker and Christine Hodgdon to learn more about tissue donation programs and how they can help accelerate scientific research. Tissue donation programs ask patients to consider donating their tissues, including organs, soon after we die to help researchers better understand how breast cancer continues to spread and how to slow it down or stop it altogether. Donating our tissue is one way we can help thousands of other women and men with MBC to live longer with higher quality of life.
Report Back from SABCS 2023: Spotlight on the Latest in MBC
Today we are bringing you a special episode that we created in partnership with SHARE Cancer Support. It’s an audio version of a live webinar that was done this past February called Report Back from San Antonio Breast Cancer Symposium 2023. SABCS is the world’s leading breast cancer research meeting where scientists, patient advocates, and others dedicated to working in the field of cancer gather. In this podcast, Dr. Timothy Pluard highlighted promising research, targeted therapy, the evolving treatment after CDK 4/6 inhibitors, liquid biopsy and more.
Understanding Progression: How to Identify & Treat ESR1 Mutations in HR+ MBC
Today we are bringing you a special podcast that we created in partnership with SHARE Cancer Support called Understanding Progression: How to Identify and Treat ESR1 Mutations in HR+ MBC. This episode was produced from a live webinar from this past October. There has not been a new endocrine treatment in decades and many of us find out the endocrine treatment no longer works for us because the cancer has mutated. Kate Vieira Pfitzer and Victoria Goldberg are excited to bring Dr. Virginia Kaklamani to you. You will hear her explain this common problem, how to test for it, the new treatment option that is now available as well as many of the ongoing clinical trials for HR+ MBC.
Report Back From ASCO 2023: What’s the Latest News in MBC Research?
Dr. Sherry Shen, breast oncologist from Memorial Sloan Kettering Cancer Center, breaks down the recent research from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. She will present new findings in Metastatic Breast Cancer research.
Recent Advances, Controversies, and Emerging Trends in MBC
Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.
2022 in Review: Best in MBC with Dr. Erika Hamilton
Welcome to the first Road to A Cure episode of Season 6. Our guest is the incomparable Dr. Erika Hamilton, a breast oncologist and researcher who, as she says herself, doesn’t shy away from difficult questions. In this episode, we get a review—subtype by subtype—of the biggest news over the past 15 months. Of course, we also talk about what is on the horizon in MBC.
ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.
Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?
MSK’s Dr. Shanu Modi, lead investigator on the DESTINY-Breast04 trial, talks with the Our MBC Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.
MBC101: The HER2-Low Show
The DESTINY-Breast04 trial at ASCO 2022 introduced many people to the term “HER2-low.” But how do you know if you’re HER2-low? In this episode, with the help a breast pathologist and a clinical oncologist we dive into this subtype and what it means to us.
Report Back from ASCO 2022: What’s the Latest in MBC Research?
The biggest cancer conference in the world, the American Society of Clinical Oncology (ASCO) 2022 annual meeting, was back in person after 2 years online during the COVID pandemic. Some of the research highlights presented this year are “practice-changing.” and received a rarely given standing ovation. What is practice changing in MBC? Get the answer to this question and a lot more in the report back from ASCO
Dr. Nancy Lin: Are CNS Mets Becoming More Treatable? What’s New with STOP-HER2?
Brain metastases are unfortunately an all too common and devastating complication of breast cancer. The blood-brain barrier has long been a key obstacle to developing effective systemic therapies; however, newer agents are showing signs of overcoming this challenge. Dr. Nancy Lin explains.
ER Progression and Resistance: Causes, Consequences, and Hope
Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.
Report Back from SABCS 2021: What’s the Latest in MBC Research?
Learn about the most recent information released at the annual San Antonio Breast Cancer Symposium regarding metastatic breast cancer research with Dr. Peter Schmid, Professor of Cancer Medicine at Barts Cancer Institute in London, England. Dr. Schmid will provide a comprehensive update and answer your questions about these new developments.